Why Biohaven Stock Crushed it on Monday
Source: Motley Fool
2026-04-13 18:01:57 ET
Biohaven (NYSE: BHVN) stock got quite the shot in the arm as the trading week began. On Monday, an analyst initiated coverage of the clinical-stage biotech with a very bullish buy recommendation; not suprisingly, investors took this to heart and pushed the price of the shares up by more than 10% that trading session.
The person behind the initiation was Canaccord Genuity's Sumant Kulkami, who flagged Biohaven as a buy with a price target of $21 per share. That figure is significant, as it's more than double Biohaven's present level, even after the Monday price pop.
Image source: Getty Images.
Biohaven Ltd.
NASDAQ: BHVN
BHVN Trading
-3.93% G/L:
$10.825 Last:
890,011 Volume:
$11.33 Open:
BHVN Latest News
June 01, 2026 07:30:00 am
Biohaven Reports First-in-Human Dosing of Oral PKM2 Modulator, BHV-8100, Targeting Metabolic Restoration and Immunomodulation
May 27, 2026 07:30:00 am
Biohaven Reports Positive Clinical Biomarker and Patient Data: First MoDE and TRAP Extracellular Protein Degraders Achieve Deep, Rapid, Selective Lowering of Disease-Driving Antibodies in Graves' Disease and IgA Nephropathy
BHVN Stock Data
$1,610,213,046
113,271,989
1.64%
9
N/A
Biotechnology & Life Sciences
Healthcare
US
New Haven
